| human | Q5 |
| P496 | ORCID iD | 0000-0002-4738-8298 |
| P735 | given name | Isabelle | Q6078151 |
| Isabelle | Q6078151 | ||
| P106 | occupation | researcher | Q1650915 |
| Q42677844 | "Trust is not something you can reclaim easily": patenting in the field of direct-to-consumer genetic testing |
| Q38560900 | A bacteriophage journey at the European Medicines Agency |
| Q86248155 | Access to biobanks: harmonization across biobank initiatives |
| Q35595468 | Access to human tissues for research and product development: From EU regulation to alarming legal developments in Belgium |
| Q33740641 | Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel |
| Q92047763 | An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? |
| Q42320882 | Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012 |
| Q37976334 | Biosimilars and market access: a question of comparability and costs? |
| Q94648773 | Biosimilars in Belgium: a proposal for a more competitive market |
| Q37338114 | Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems |
| Q37631618 | Call for a dedicated European legal framework for bacteriophage therapy. |
| Q86537961 | Causes of drug shortages in the legal pharmaceutical framework |
| Q49142488 | Chemotherapy drug shortages in paediatric oncology: A 14-year single-centre experience in Belgium. |
| Q39536773 | Clinical, Economic and Policy Implications of Drug Shortages in the European Union. |
| Q92069916 | Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study |
| Q64899490 | Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting. |
| Q64891473 | Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting. |
| Q34677617 | Drug shortages in European countries: a trade-off between market attractiveness and cost containment? |
| Q91876826 | Economic evaluation of biosimilars for reimbursement purposes - what, when, how? |
| Q101212671 | European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption |
| Q100664577 | European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice |
| Q46375866 | European drug shortages: a call for action! |
| Q52604672 | Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains. |
| Q90755973 | Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US |
| Q91857970 | Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review |
| Q49162947 | Financial based agreements and performance based agreements: the Belgian experience. |
| Q35303964 | Gene and genetic diagnostic method patent claims: a comparison under current European and US patent law |
| Q91624640 | Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! |
| Q100496464 | Implementation of Electronic Informed Consent in Biomedical Research and Stakeholders' Perspectives: Systematic Review |
| Q90765110 | Improving Patient Preference Elicitation by Applying Concepts From the Consumer Research Field: Narrative Literature Review |
| Q30383258 | Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs |
| Q64039387 | Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium |
| Q47152987 | Innovative Approaches to Increase Access to Medicines in Developing Countries |
| Q28607506 | Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs) |
| Q28544114 | Insights into European drug shortages: a survey of hospital pharmacists |
| Q50855538 | Intellectual property policies in early-phase research in public-private partnerships. |
| Q51878296 | Key issues in phage therapy: a report of a dedicated workshop at the Viruses of Microbes II meeting. |
| Q84682906 | Legal uncertainty in the area of genetic diagnostic testing |
| Q30843820 | Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future |
| Q38163486 | Market access of cancer drugs in European countries: improving resource allocation |
| Q47266726 | Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges |
| Q91942192 | Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review |
| Q88528817 | Noninvasive prenatal testing: a survey of young (future) parents in Flanders |
| Q89792747 | On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients |
| Q90488100 | Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review |
| Q38004869 | Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine |
| Q91714385 | Patient Centricity in Patient Preference Studies: The Patient Perspective |
| Q58572925 | Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice |
| Q92921540 | Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA |
| Q37281307 | Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. |
| Q47656264 | Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. |
| Q47173303 | Policies for biosimilar uptake in Europe: An overview. |
| Q50918560 | Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013. |
| Q91790394 | Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications |
| Q64078152 | Protection of Phage Applications in Crop Production: A Patent Landscape |
| Q42650006 | Public Views on Genetics and Genetic Testing: A Survey of the General Public in Belgium |
| Q28603538 | Qualitative study on custodianship of human biological material and data stored in biobanks |
| Q35674419 | Quality and safety requirements for sustainable phage therapy products |
| Q88693139 | Repurposing Drugs in Oncology: Next Steps |
| Q92943665 | Repurposing drugs in oncology: From candidate selection to clinical adoption |
| Q89967729 | Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective |
| Q48505941 | Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. |
| Q33608714 | Taking bacteriophage therapy seriously: a moral argument |
| Q44980774 | The European BRCA patent oppositions and appeals: coloring inside the lines |
| Q50055222 | The Magistral Phage |
| Q33774645 | The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape |
| Q57923584 | The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure? |
| Q93139736 | The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars |
| Q90823298 | The efficacy, safety and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review |
| Q49220732 | The fate and future of patents on human genes and genetic diagnostic methods |
| Q89418853 | The necessity for a European definition of drug shortages |
| Q41526726 | Time Investment in Drug Supply Problems by Flemish Community Pharmacies |
| Q36325432 | Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study |
| Q36226420 | Toward a European definition for a drug shortage: a qualitative study |
| Q50052181 | Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology |
| Q93037010 | Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies |
| Q89964214 | Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making |
| Q92269402 | What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population |
Search more.